Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-Current Assets (2016 - 2025)

Amphastar Pharmaceuticals has reported Non-Current Assets over the past 13 years, most recently at $353.7 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $353.7 million for Q4 2025, up 2.64% from a year ago — trailing twelve months through Dec 2025 was $353.7 million (up 2.64% YoY), and the annual figure for FY2025 was $353.7 million, up 2.64%.
  • Non-Current Assets for Q4 2025 was $353.7 million at Amphastar Pharmaceuticals, roughly flat from $353.5 million in the prior quarter.
  • Over the last five years, Non-Current Assets for AMPH hit a ceiling of $899.3 million in Q3 2023 and a floor of $259.8 million in Q3 2022.
  • Median Non-Current Assets over the past 5 years was $321.6 million (2023), compared with a mean of $420.3 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 246.15% in 2023 and later tumbled 63.58% in 2024.
  • Amphastar Pharmaceuticals' Non-Current Assets stood at $271.5 million in 2021, then decreased by 2.55% to $264.6 million in 2022, then rose by 19.3% to $315.6 million in 2023, then grew by 9.18% to $344.6 million in 2024, then rose by 2.64% to $353.7 million in 2025.
  • The last three reported values for Non-Current Assets were $353.7 million (Q4 2025), $353.5 million (Q3 2025), and $354.7 million (Q2 2025) per Business Quant data.